ArticleClinical and translational science2010
A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release.
Article in Clinical and translational science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Human Lung Mast Cells as a Possible Reservoir for Coronavirus: A Novel Unrecognized Mechanism for SARS-CoV-2 Immune-Mediated Pathology.International journal of molecular sciences · 2024Article
- Description and Characterization of Three-Dimensional Human Mast Cell Progenitor Spheroids In Vitro.Cureus · 2024Article
- Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy.Frontiers in oncology · 2022Article
- Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer.Frontiers in oncology · 2022Review
- Review
- A Phosphatase-Mimetic Nano-Stabilizer of Mast Cells for Long-Term Prevention of Allergic Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Engineered Nanomaterials and Type I Allergic Hypersensitivity Reactions.Frontiers in immunology · 2020Review
- Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells.Frontiers in immunology · 2019Article
- Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis.Journal of nanobiotechnology · 2016Article
- Article
- A steroid-mimicking nanomaterial that mediates inhibition of human lung mast cell responses.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- IL-33/ST2 axis promotes mast cell survival via BCLXL.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system.Toxicological sciences : an official journal of the Society of Toxicology · 2014Review
- Engineered nanomaterial exposure and the risk of allergic disease.Current opinion in allergy and clinical immunology · 2014Review
- Twenty-first century mast cell stabilizers.British journal of pharmacology · 2013Review
- Immunotoxicological impact of engineered nanomaterial exposure: mechanisms of immune cell modulation.Toxicology mechanisms and methods · 2013Review
- Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2013Article
- Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma.The Journal of allergy and clinical immunology · 2012Article
- Manufactured and airborne nanoparticle cardiopulmonary interactions: a review of mechanisms and the possible contribution of mast cells.Inhalation toxicology · 2012Review
- Mediators released during human anaphylaxis.Current allergy and asthma reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Treatments for allergic disease block the effects of mediators released from activated mast cells and blood basophils. A panel of fullerene derivatives was synthesized and tested for their ability to preempt the release of allergic mediators in vitro and in vivo. The fullerene C(70)-tetraglycolic acid significantly inhibited degranulation and cytokine production from mast cells and basophils, while C(70)-tetrainositol blocked only cytokine production in mast cells and degranulation and cytokine production in basophils. The early phase of FcepsilonRI inhibition was dependent on the blunted release of intracellular calcium stores, elevations in reactive oxygen species, and several signaling molecules. Gene microarray studies further showed the two fullerene derivatives inhibited late phase responses in very different ways. C(70)-tetraglycolic acid was able to block mast cell-driven anaphylaxis in vivo, while C(70)-tetrainositol did not. No toxicity was observed with either compound. These findings demonstrate the biological effects of fullerenes critically depends on the moieties added to the carbon cage and suggest they act on different FcepsilonRI-specific molecules in mast cells and basophils. These next generation fullerene derivatives represent a new class of compounds that interfere with FcepsilonRI signaling pathways to stabilize mast cells and basophils. Thus, fullerene-based therapies may be a new approach for treating allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.